Peptic ulcer disease. Clinical evaluation in 2006;Ulkuskrankheit. Klinische bewertung 2006

Internist

Volumn 47, Issue 6, 2006, Pages 588-595

  Malfertheiner, P ^a   Bellutti, M ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Eradication therapy; Helicobacter pylori; Nonsteroidal antirheumatic agents; Peptic ulcer; Proton pump inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR;

ACID SECRETION; ANTIBIOTIC THERAPY; ARTICLE; DUODENUM ULCER; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; NONHUMAN; PEPTIC ULCER;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PRACTICE GUIDELINES AS TOPIC;

EID: 33745179586     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-006-1630-y     Document Type: Article

References (30)

1. Sipponen P (1992) Natural history of gastritis and its relationship to peptic ulcer disease. Digestion 51 [Suppl 1]: 70-75
2. McColl KE, el-Omar E (1996) Helicobacter pylori and disturbance of gastric function associated with duodenal ulcer disease and gastric cancer. Scand J Gastroenterol [Suppl] 215: 32-37
3. Malfertheiner P, Bode G (1993) Helicobacter pylori and the pathogenesis of duodenal ulcer disease. Eur J Gastroenterol Hepatol 5 [Suppl 1]: 51-58
4. D'Elios MM, Amedei A, Del Prete G (2003) Helicobacter pylori antigen-specific T-cell responses at gastric level in chronic gastritis, peptic ulcer, gastric cancer and low-grade mucosa-associated lymphoid tissue (MALT) lymphoma. Microbes Infect 5:723-730
5. McColl KE, el-Omar EM, Gillen D (1997) Alterations in gastric physiology in Helicobacter pylori infection: causes of different diseases or all epiphenomena? Ital J Gastroenterol Hepatol 29: 459-464
6. Lu H, Yamaoka Y, Graham DY (2005) Helicobacter pylori virulence factors: facts and fantasies. Curr Opin Gastroenterol 21: 653-659
7. Whittle BJ (2003) Gastrointestinal effects of non-steroidal anti-inflammatory drugs. Fundam Clin Pharmacol 17: 301-313
8. Flower RJ (2003) The development of COX2 inhibitors. Nat Rev Drug Discov 2: 179-191
9. Dogne JM, Hanson J, Supuran C, Pratico D (2006) Coxibs and cardiovascular side-effects: from light to shadow. Curr Pharm Des 12: 971-975
10. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP (2003) Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis 62: 501-509
11. Treiber G, Wex T, Link A et al. (2006) The effect of single-dose naproxen on eicosanoid formation in human gastroduodenal mucosa. Aliment Pharmacol Ther 23: 155-167
12. Huang JQ, Sridhar S, Hunt RH (2002) Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359 (9300): 14-22
13. Malfertheiner P, Kirchner T, Kist M et al.; BYK Advanced Gastric Ulcer Study Group (2003) Helicobacter pylori eradication and gastric ulcer healing - comparison of three pantoprazole-based triple therapies. Aliment Pharmacol Ther 17: 1125-1135
14. Ford AC, Qume M, Moayyedi P et al. (2005) Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis. Gastroenterology 128: 1838-1844
15. Treiber G, Kist M, Klotz U et al. (2005) Therapie der Helicobacter-pylori-Infektion: Klinische, mikrobiologische und pharmakologische Aspekte. Dtsch Arztebl 102: A1883-1888
16. Goddard A, Jessa M, Barrett D et al. (1996)Effect of omeprazoleon the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 111: 358-367
17. Vakil N, Lanza F, Schwartz H, Barth J (2004) Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 20: 99-107
18. Peitz U, Sulliga M, Wolle K et al. (2002) High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomised study. Aliment Pharmacol Ther 16: 315-324
19. Labenz J, Tillenburg B, Peitz U et al. (1996) Ulkusheilung durch Helicobacter pylori Eradikation: genügt eine Woche Therapie? Dtsch Med Wochenschr 121: 3
20. Graham DY, Agrawal NM, Campbell DR et al. (2002) NSAID-Associated Gastric Ulcer Prevention Study Group. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active-and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162: 169-175
21. Silverstein FE, Faich G, Goldstein JL et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: 1247-1255
22. Lai KC, Chu KM, Hui WM et al. (2005) Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med 118: 1271-1278
23. Scheiman JM, Yeomans ND, Talley NJ et al. (2006) Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 Inhibitors. Am J Gastroenterol 22 [Epub ahead of print]
24. Stupnicki T, Dietrich K, Gonzalez-Carro P et al. (2003) Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion 68: 198-208
25. Chan FK, To KF, Wu JC et al. (2002) Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 359 (9300): 9-13
26. Goldstein JL, Johanson JF, Suchower LJ, Brown KA (2005) Healing of gastric ulcers with esomeprazole versus ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 100: 2650-2657
27. Chan FK (2005) NSAID-induced peptic ulcers and Helicobacter pylori infection: implications for patient management. Drug Saf 28: 287-300
28. Hawkey C, Talley NJ, Yeomans ND et al.; NASA1 SPACE1 Study Group (2005) Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 100: 1028-1036
29. Leontiadis GI, Sharma VK, Howden CW (2005) Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding. BMJ 330: 568
30. Chan FK, Ching JY, Hung LC et al. (2005) Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238-244